Teva Settles Provigil Pay-For-Delay Class Action; Will FTC Deal Follow?
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva plays it safe in $512 million agreement with direct purchasers, even though AstraZeneca won a jury verdict in similar suit, the first to go to trial since Supreme Court’s FTC v. Actavis decision.